$NVCR
NovoCure Ltd Stock $nvcr

$nvcr Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-Q Financial Statement

#000164511322000043 Filed on April 28, 2022

Income Statement

Concept	2022 Q1	2021 Q1
Revenue	$137.5M	$134.7M
YoY Change	2.12%	32.28%
Cost Of Revenue	$27.73M	$26.39M
YoY Change	5.09%	7.71%
Gross Profit	$109.8M	$108.3M
YoY Change	1.39%	40.06%
Gross Profit Margin	79.84%	80.41%
Selling, General & Admin	$68.39M	$62.48M
YoY Change	9.46%	12.7%
% of Gross Profit	62.28%	57.69%
Research & Development	$42.23M	$45.92M
YoY Change	-8.02%	81.69%
% of Gross Profit	38.46%	42.39%
Depreciation & Amortization	$2.610M	$2.370M
YoY Change	10.13%	25.4%
% of Gross Profit	2.38%	2.19%
Operating Expenses	$110.6M	$108.4M
YoY Change	2.06%	34.3%
Operating Profit	-$806.0K	-$88.00K
YoY Change	815.91%	-97.4%
Interest Expense	-$1.709M	-$2.600M
YoY Change	-34.27%	8.33%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$2.515M	-$2.734M
YoY Change	-8.01%	-52.97%
Income Tax	$2.132M	$1.394M
% Of Pretax Income
Net Earnings	-$4.647M	-$4.128M
YoY Change	12.57%	-204.45%
Net Earnings / Revenue	-3.38%	-3.06%
Basic Earnings Per Share	-$0.04	-$0.04
Diluted Earnings Per Share	-$0.04	-$0.04
COMMON SHARES
Basic Shares Outstanding	104.2M shares	102.6M shares
Diluted Shares Outstanding	104.2M shares	102.6M shares

Balance Sheet

Concept	2022 Q1	2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$932.3M	$864.4M
YoY Change	7.86%	160.91%
Cash & Equivalents	$190.7M	$314.5M
Short-Term Investments	$744.1M	$549.9M
Other Short-Term Assets	$889.0K	$11.40M
YoY Change	-92.2%	1325.0%
Inventory	$29.08M	$27.97M
Prepaid Expenses
Receivables	$101.0M	$92.51M
Other Receivables	$17.34M	$18.90M
Total Short-Term Assets	$1.081B	$1.015B
YoY Change	6.44%	119.66%
LONG-TERM ASSETS
Property, Plant & Equipment	$25.07M	$11.73M
YoY Change	113.69%	19.99%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$11.83M	$10.79M
YoY Change	9.63%	123.63%
Total Long-Term Assets	$69.63M	$52.39M
YoY Change	32.89%	30.11%
TOTAL ASSETS
Total Short-Term Assets	$1.081B	$1.015B
Total Long-Term Assets	$69.63M	$52.39M
Total Assets	$1.150B	$1.068B
YoY Change	7.73%	112.49%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$69.19M	$52.70M
YoY Change	31.28%	30.45%
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$127.8M	$110.5M
YoY Change	15.67%	31.22%
LONG-TERM LIABILITIES
Long-Term Debt	$563.0M	$559.6M
YoY Change	0.62%	274.39%
Other Long-Term Liabilities	$156.0K	$177.0K
YoY Change	-11.86%	-33.71%
Total Long-Term Liabilities	$586.5M	$585.0M
YoY Change	0.26%	231.83%
TOTAL LIABILITIES
Total Short-Term Liabilities	$127.8M	$110.5M
Total Long-Term Liabilities	$586.5M	$585.0M
Total Liabilities	$714.3M	$695.5M
YoY Change	2.71%	166.99%
SHAREHOLDERS EQUITY
Retained Earnings	-$690.6M	-$631.7M
YoY Change	9.32%	-2.35%
Common Stock	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$435.9M	$372.1M
YoY Change
Total Liabilities & Shareholders Equity	$1.150B	$1.068B
YoY Change	7.73%	112.49%

Cashflow Statement

Concept	2022 Q1	2021 Q1
OPERATING ACTIVITIES
Net Income	-$4.647M	-$4.128M
YoY Change	12.57%	-204.45%
Depreciation, Depletion And Amortization	$2.610M	$2.370M
YoY Change	10.13%	25.4%
Cash From Operating Activities	-$3.687M	$17.78M
YoY Change	-120.74%	808.53%
INVESTING ACTIVITIES
Capital Expenditures	$5.093M	$3.981M
YoY Change	27.93%	27.92%
Acquisitions
YoY Change
Other Investing Activities	-$12.32M	$58.15M
YoY Change	-121.18%
Cash From Investing Activities	-$17.41M	$54.17M
YoY Change	-132.14%	-1840.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$0.00
YoY Change
Debt Paid & Issued, Net	$7.000K	$6.000K
YoY Change	16.67%	-25.0%
Cash From Financing Activities	$3.141M	$7.955M
YoY Change	-60.52%	76.66%
NET CHANGE
Cash From Operating Activities	-$3.687M	$17.78M
Cash From Investing Activities	-$17.41M	$54.17M
Cash From Financing Activities	$3.141M	$7.955M
Net Change In Cash	-$17.98M	$79.80M
YoY Change	-122.53%	2326.39%
FREE CASH FLOW
Cash From Operating Activities	-$3.687M	$17.78M
Capital Expenditures	$5.093M	$3.981M
Free Cash Flow	-$8.780M	$13.80M
YoY Change	-163.63%	-1294.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q1	dei	Amendment Flag AmendmentFlag	false
CY2022Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2022Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001645113
CY2022Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Accounting Standards Update Extensible List AccountingStandardsUpdateExtensibleList	http://fasb.org/us-gaap/2021-01-31#AccountingStandardsUpdate202006Member
CY2022Q1	dei	Document Type DocumentType	10-Q
CY2022Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	dei	Document Period End Date DocumentPeriodEndDate	2022-03-31
CY2022Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	dei	Entity File Number EntityFileNumber	001-37565
CY2022Q1	dei	Entity Registrant Name EntityRegistrantName	NovoCure Limited
CY2022Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	Y9
CY2022Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1057807
CY2022Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	No. 4 The Forum
CY2022Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Grenville Street
CY2022Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	St. Helier
CY2022Q1	dei	Entity Address Country EntityAddressCountry	JE
CY2022Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	JE2 4UF
CY2022Q1	dei	City Area Code CityAreaCode	44 (0) 15
CY2022Q1	dei	Local Phone Number LocalPhoneNumber	3475 6700
CY2022Q1	dei	Security12b Title Security12bTitle	Ordinary Shares, no par value
CY2022Q1	dei	Trading Symbol TradingSymbol	NVCR
CY2022Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2022Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2022Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	104586094	shares
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	190739000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	208802000	USD
CY2022Q1	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	741562000	USD
CY2021Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	728898000	USD
CY2022Q1	us-gaap	Restricted Cash Current RestrictedCashCurrent	889000	USD
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	807000	USD
CY2022Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	100965000	USD
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	93567000	USD
CY2022Q1	nvcr	Receivables And Prepaid Expenses ReceivablesAndPrepaidExpenses	17343000	USD
CY2021Q4	nvcr	Receivables And Prepaid Expenses ReceivablesAndPrepaidExpenses	17025000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	29084000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	24427000	USD
CY2022Q1	us-gaap	Assets Current AssetsCurrent	1080582000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	1073526000	USD
CY2022Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	25072000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22693000	USD
CY2022Q1	nvcr	Field Equipment Net Noncurrent FieldEquipmentNetNoncurrent	12792000	USD
CY2021Q4	nvcr	Field Equipment Net Noncurrent FieldEquipmentNetNoncurrent	12923000	USD
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	19937000	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18267000	USD
CY2022Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	11827000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	12086000	USD
CY2022Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	69628000	USD
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	65969000	USD
CY2022Q1	us-gaap	Assets Assets	1150210000	USD
CY2021Q4	us-gaap	Assets Assets	1139495000	USD
CY2022Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	69186000	USD
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	72600000	USD
CY2022Q1	nvcr	Other Accounts Payable Lease Liabilities And Accrued Expenses Current OtherAccountsPayableLeaseLiabilitiesAndAccruedExpensesCurrent	58613000	USD
CY2021Q4	nvcr	Other Accounts Payable Lease Liabilities And Accrued Expenses Current OtherAccountsPayableLeaseLiabilitiesAndAccruedExpensesCurrent	70002000	USD
CY2022Q1	us-gaap	Liabilities Current LiabilitiesCurrent	127799000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	142602000	USD
CY2022Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	563026000	USD
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	562216000	USD
CY2022Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	5511000	USD
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	6477000	USD
CY2022Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14813000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12997000	USD
CY2022Q1	nvcr	Employee Related Liabilities Non Current EmployeeRelatedLiabilitiesNonCurrent	3024000	USD
CY2021Q4	nvcr	Employee Related Liabilities Non Current EmployeeRelatedLiabilitiesNonCurrent	4543000	USD
CY2022Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	156000	USD
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	166000	USD
CY2022Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	586530000	USD
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	586399000	USD
CY2022Q1	us-gaap	Liabilities Liabilities	714329000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	729001000	USD
CY2022Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2022Q1	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2022Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	104559088	shares
CY2022Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	104559088	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	103971263	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	103971263	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2022Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1127782000	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1099589000	USD
CY2022Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1328000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-3169000	USD
CY2022Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-690573000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-685926000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	435881000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	410494000	USD
CY2022Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1150210000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	1139495000	USD
CY2022Q1	us-gaap	Revenues Revenues	137547000	USD
CY2021Q1	us-gaap	Revenues Revenues	134695000	USD
CY2021	us-gaap	Revenues Revenues	535031000	USD
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	27727000	USD
CY2021Q1	us-gaap	Cost Of Revenue CostOfRevenue	26385000	USD
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	114877000	USD
CY2022Q1	us-gaap	Gross Profit GrossProfit	109820000	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	108310000	USD
CY2021	us-gaap	Gross Profit GrossProfit	420154000	USD
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	42234000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	45916000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	201303000	USD
CY2022Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	37884000	USD
CY2021Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	31357000	USD
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	137057000	USD
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	30508000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31125000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	126127000	USD
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	110626000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	108398000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	464487000	USD
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-806000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-88000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-44333000	USD
CY2022Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense	1709000	USD
CY2021Q1	us-gaap	Interest And Debt Expense InterestAndDebtExpense	2646000	USD
CY2021	us-gaap	Interest And Debt Expense InterestAndDebtExpense	7742000	USD
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2515000	USD
CY2021Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2734000	USD
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-52075000	USD
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	2132000	USD
CY2021Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1394000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6276000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4647000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-4128000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58351000	USD
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.56
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104186120	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102633545	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	103433274	shares
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.56
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	104186120	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	102633545	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	103433274	shares
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4647000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-4128000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58351000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	330000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-268000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	302000	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-1511000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-2152000	USD
CY2021	us-gaap	Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax	-361000	USD
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2806000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2244000	USD
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-57688000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	410494000	USD
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25045000	USD
CY2022Q1	nvcr	Stock Issued During Period Value Stock Options Exercised And Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockAwardForfeitures	3148000	USD
CY2021Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1841000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4647000	USD
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	435881000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	476526000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	18863000	USD
CY2021Q1	nvcr	Stock Issued During Period Value Stock Options Exercised And Restricted Stock Award Forfeitures StockIssuedDuringPeriodValueStockOptionsExercisedAndRestrictedStockAwardForfeitures	7961000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Loss Tax OtherComprehensiveIncomeLossTax	0	USD
CY2021Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	1884000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-4128000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	372134000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4647000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-4128000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58351000	USD
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2610000	USD
CY2021Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	2370000	USD
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	10251000	USD
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-221000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	0	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-94000	USD
CY2022Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	135000	USD
CY2021Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-2157000	USD
CY2021Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	176000	USD
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	649000	USD
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	25045000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	18863000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	94900000	USD
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-249000	USD
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-3231000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7461000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4624000	USD
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-5270000	USD
CY2022Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	684000	USD
CY2021Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	603000	USD
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	3101000	USD
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4804000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1296000	USD
CY2021	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-2483000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1863000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1432000	USD
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-4519000	USD
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-14809000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-2626000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	27777000	USD
CY2022Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-2331000	USD
CY2021Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-4394000	USD
CY2021	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-10980000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3687000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	17780000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	82756000	USD
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5093000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	3981000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	24170000	USD
CY2022Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	279000000	USD
CY2021Q1	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	608000000	USD
CY2021	us-gaap	Proceeds From Maturities Prepayments And Calls Of Held To Maturity Securities ProceedsFromMaturitiesPrepaymentsAndCallsOfHeldToMaturitySecurities	958000000	USD
CY2022Q1	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	291317000	USD
CY2021Q1	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	549848000	USD
CY2021	us-gaap	Payments To Acquire Held To Maturity Securities PaymentsToAcquireHeldToMaturitySecurities	1078664000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-17410000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	54171000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-144834000	USD
CY2022Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4546000	USD
CY2022Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	7000	USD
CY2021Q1	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	6000	USD
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	26000	USD
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3148000	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25702000	USD
CY2022Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-25000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7961000	USD
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	21182000	USD
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3141000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7955000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-102000	USD
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-188000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-17981000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	79804000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-36564000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	209609000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	246173000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	246173000	USD
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	191628000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	325977000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	209609000	USD
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1173000	USD
CY2021Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	-2405000	USD
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3110000	USD
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet	1000	USD
CY2021Q1	us-gaap	Interest Paid Net InterestPaidNet	1000	USD
CY2021	us-gaap	Interest Paid Net InterestPaidNet	101000	USD
CY2022Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3580000	USD
CY2021Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	284000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	5387000	USD
CY2022Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	190739000	USD
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	208802000	USD
CY2022Q1	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	741562000	USD
CY2021Q4	us-gaap	Held To Maturity Securities Current HeldToMaturitySecuritiesCurrent	728898000	USD
CY2022Q1	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	741562000	USD
CY2021Q4	us-gaap	Held To Maturity Securities Fair Value HeldToMaturitySecuritiesFairValue	728906000	USD
CY2022Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1831000	USD
CY2021Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1485000	USD
CY2022Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	14010000	USD
CY2021Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	8274000	USD
CY2022Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	13243000	USD
CY2021Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	14668000	USD
CY2022Q1	us-gaap	Inventory Net InventoryNet	29084000	USD
CY2021Q4	us-gaap	Inventory Net InventoryNet	24427000	USD
CY2022Q1	us-gaap	Deposits Assets DepositsAssets	2344000	USD
CY2021Q4	us-gaap	Deposits Assets DepositsAssets	2350000	USD
CY2022Q1	us-gaap	Contractual Obligation ContractualObligation	2692000	USD
CY2021Q4	us-gaap	Contractual Obligation ContractualObligation	2698000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8549322	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	33.09
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	575246	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	80.59
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	175650	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	18.14
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	13467	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	77.31
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	8935451	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	36.38
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	5787733	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	24.15
CY2022Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	175650	shares
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25045000	USD
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	18863000	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	94900000	USD
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4647000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-4128000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58351000	USD
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104186120	shares
CY2021Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	102633545	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	103433274	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	104186120	shares
CY2021Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	102633545	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	103433274	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7874118	shares
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9734269	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8524922	shares
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2021Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.56
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2021Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.04
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.56
CY2022Q1	us-gaap	Noncurrent Assets NoncurrentAssets	37864000	USD
CY2021Q4	us-gaap	Noncurrent Assets NoncurrentAssets	35616000	USD
CY2022Q1	us-gaap	Revenues Revenues	137547000	USD
CY2021Q1	us-gaap	Revenues Revenues	134695000	USD
CY2021	us-gaap	Revenues Revenues	535031000	USD

Files In Submission

Name	View Source	Status
0001645113-22-000043-index-headers.html	Edgar Link	pending
0001645113-22-000043-index.html	Edgar Link	pending
0001645113-22-000043.txt	Edgar Link	pending
0001645113-22-000043-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nvcr-20220331.htm	Edgar Link	pending
nvcr-20220331.xsd	Edgar Link	pending
nvcr-20220331exx311.htm	Edgar Link	pending
nvcr-20220331xexx312.htm	Edgar Link	pending
nvcr-20220331xexx321.htm	Edgar Link	pending
nvcr-20220331xexx322.htm	Edgar Link	pending
nvcr-20220331_cal.xml	Edgar Link	unprocessable
nvcr-20220331_def.xml	Edgar Link	unprocessable
nvcr-20220331_g1.jpg	Edgar Link	pending
nvcr-20220331_htm.xml	Edgar Link	completed
nvcr-20220331_lab.xml	Edgar Link	unprocessable
nvcr-20220331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NVCR
NovoCure Ltd Stock $nvcr

2022 Q1 Form 10-Q Financial Statement

#000164511322000043 Filed on April 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVCR NovoCure Ltd Stock $nvcr

2022 Q1 Form 10-Q Financial Statement

#000164511322000043 Filed on April 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NVCR
NovoCure Ltd Stock $nvcr